Singapore markets closed

VRTX Jan 2024 195.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.28000.0000 (0.00%)
As of 10:20AM EST. Market open.
Full screen
Previous close0.2800
Expiry date2024-01-19
Day's range0.2500 - 2.3500
Contract rangeN/A
Open interest28
  • Motley Fool

    5 Top Stocks to Buy Before 2024

    One area to focus on is companies that generally offer steady earnings growth over time. CRISPR Therapeutics (NASDAQ: CRSP) just reached a huge milestone, and another may be just ahead. The company recently won the world's first authorization for a CRISPR-based gene-editing treatment when the U.K. gave the nod to exa-cel (to be commercialized as Casgevy).

  • Motley Fool

    Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?

    Biotech companies CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals (NASDAQ: VRTX) are often mentioned in the same sentence. Vertex is a much larger company with proven innovative abilities, and it has generated strong and consistent revenue, earnings, and stock-market performance in the past decade. CRISPR is a much younger company with a much shorter track record, but could it one day become as successful as its larger partner?

  • CNW Group

    Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older

    Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Market Authorization for the expanded use of PrKALYDECO® (ivacaftor) for the treatment of cystic fibrosis (CF) in children ages 2 months and older weighing at least 3 kg who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R or R117H.